Over $9 billion star drug Qilu is the first
domestic product to be reported for production. Qilu pharmaceutical obtained
the acceptance of CDE for the listing application of Aflibercept intraocular
injection solution submitted by new drug category 3.3, which is the first
reported production of Aflibercept biological similar drug in China.
2022-07-18
Shanghai, China